Gilead and Tubulis Enter Exclusive Option and License Agreement to Develop Antibody Drug Conjugate That Targets Solid Tumors

Gilead Sciences and Tubulis Agreement

Gilead Sciences (GILD) and Tubulis announced that they entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. Gilead will gain access to Tubulis’ proprietary Tubutecan and Alco5 platforms.

The companies will collaborate to . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.